H.C. Wainwright Keeps Their Buy Rating on Protalix Biotherapeutics (PLX)


In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Protalix Biotherapeutics (PLX), with a price target of $4. The company’s shares closed yesterday at $0.45.

According to TipRanks.com, Selvaraju is ranked 0 out of 5 stars with an average return of -12.3% and a 31.4% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, EyePoint Pharmaceuticals Inc, and Bausch Health Companies Inc.

Currently, the analyst consensus on Protalix Biotherapeutics is a Moderate Buy with an average price target of $4.

See today’s analyst top recommended stocks >>

The company has a one-year high of $0.83 and a one-year low of $0.27. Currently, Protalix Biotherapeutics has an average volume of 621.4K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Protalix Biotherapeutics, Inc. engages in the development and commercialization of recombinant therapeutic proteins based on ProCellEx plant cell based expression system. It offers Taliglucerase alfa injections under the brand name Elelyso, an enzyme replacement therapy for Gaucher disease.